The study conducted on 515 patients showed a significant increase in progression-free survival at three years for patients treated with the gemcitabine chemoradiation combination versus those treated only with chemoradiation. Patients on the gemcitabine arm experienced significantly more grade 3/4 toxicities.
Results from this global, multicenter, open-label, randomized Phase III trial were presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) during an ASCO-sponsored press conference on May 31, 2009.
Richard Gaynor, Vice President of Cancer Research and Global Oncology Platform Leader for Lilly, said: Lilly continues to look for ways to improve the survival of people living with cancer and fill unmet needs in difficult to treat cancers.